Tags

Type your tag names separated by a space and hit enter

Schistosomiasis: challenges for control, treatment and drug resistance.
Curr Opin Infect Dis. 2006 Dec; 19(6):577-82.CO

Abstract

PURPOSE OF REVIEW

Schistosomiasis is a parasitic disease that has recently attracted increased focus and funding for control. Despite shifts in global health policy towards the implementation of mass chemotherapeutic control programmes at the national scale in sub-Saharan Africa, however, many challenges still exist.

RECENT FINDINGS

Publications reviewed for this article cover: the development of treatment strategies; the planning, implementation and impact of control programmes; the re-evaluation of the burden of schistosomiasis; improved tools for control; new drugs; the safety of treatment during pregnancy; and the development of resistance against praziquantel.

SUMMARY

The morbidity due to schistosomiasis has been shown to be greater than was previously thought. The reduction in morbidity of schistosomiasis by control programmes has been demonstrated, while new tools include a validated dose pole for delivering the correct treatment, geographical information systems mapping for determining high-risk areas, and Lot Quality Assurance Sampling for determining treatment strategies at the local level. Sustainability and future funding are issues to be addressed. Despite some positive results, myrrh is apparently ineffective against schistosomiasis, but fortunately no resistance to praziquantel has developed. We predict the impact of schistosomiasis control will be a healthier generation of children within 5 years.

Authors+Show Affiliations

Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London, UK. a.fenwick@imperial.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17075334

Citation

Fenwick, Alan, and Joanne P. Webster. "Schistosomiasis: Challenges for Control, Treatment and Drug Resistance." Current Opinion in Infectious Diseases, vol. 19, no. 6, 2006, pp. 577-82.
Fenwick A, Webster JP. Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis. 2006;19(6):577-82.
Fenwick, A., & Webster, J. P. (2006). Schistosomiasis: challenges for control, treatment and drug resistance. Current Opinion in Infectious Diseases, 19(6), 577-82.
Fenwick A, Webster JP. Schistosomiasis: Challenges for Control, Treatment and Drug Resistance. Curr Opin Infect Dis. 2006;19(6):577-82. PubMed PMID: 17075334.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Schistosomiasis: challenges for control, treatment and drug resistance. AU - Fenwick,Alan, AU - Webster,Joanne P, PY - 2006/11/1/pubmed PY - 2007/2/8/medline PY - 2006/11/1/entrez SP - 577 EP - 82 JF - Current opinion in infectious diseases JO - Curr. Opin. Infect. Dis. VL - 19 IS - 6 N2 - PURPOSE OF REVIEW: Schistosomiasis is a parasitic disease that has recently attracted increased focus and funding for control. Despite shifts in global health policy towards the implementation of mass chemotherapeutic control programmes at the national scale in sub-Saharan Africa, however, many challenges still exist. RECENT FINDINGS: Publications reviewed for this article cover: the development of treatment strategies; the planning, implementation and impact of control programmes; the re-evaluation of the burden of schistosomiasis; improved tools for control; new drugs; the safety of treatment during pregnancy; and the development of resistance against praziquantel. SUMMARY: The morbidity due to schistosomiasis has been shown to be greater than was previously thought. The reduction in morbidity of schistosomiasis by control programmes has been demonstrated, while new tools include a validated dose pole for delivering the correct treatment, geographical information systems mapping for determining high-risk areas, and Lot Quality Assurance Sampling for determining treatment strategies at the local level. Sustainability and future funding are issues to be addressed. Despite some positive results, myrrh is apparently ineffective against schistosomiasis, but fortunately no resistance to praziquantel has developed. We predict the impact of schistosomiasis control will be a healthier generation of children within 5 years. SN - 0951-7375 UR - https://www.unboundmedicine.com/medline/citation/17075334/Schistosomiasis:_challenges_for_control_treatment_and_drug_resistance_ L2 - http://dx.doi.org/10.1097/01.qco.0000247591.13671.6a DB - PRIME DP - Unbound Medicine ER -